By: IPP Bureau
Last updated : March 24, 2025 11:29 am
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Johnson & Johnson has broken ground on its new, 500,000 square foot, state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which will expand its capacity to deliver transformational medicines for people living with cancer, immune-mediated and neurological diseases.
This development represents a significant milestone as part of the Company’s announcement that it is increasing its U.S. research and development, technology and manufacturing investments to more than $55 billion over the next four years.
“We are pleased to make this significant investment in our manufacturing network in the United States. This state-of-the-art biologics facility in North Carolina will help Johnson & Johnson to accelerate the delivery of our portfolio and pipeline of transformational medicines for patients,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. “This $2 billion investment will bring more than 5,000 high-wage manufacturing and construction jobs to North Carolina and the partnerships we are forging in the community will support local educational initiatives to develop the workforce of the future.”
“Wilson is an important life sciences hub, and I am excited to welcome Johnson & Johnson as it expands its manufacturing footprint in our state,” said Governor Josh Stein. “I look forward to seeing the impact this investment will have on medical innovation and North Carolina’s workforce.”
This investment builds on Johnson & Johnson’s 140-year manufacturing heritage, with a significant existing footprint in the U.S. where the company already employs people in Innovative Medicine and MedTech manufacturing roles across its sites. Once fully operational, this state-of-the-art, digitally enabled facility will directly employ over 500 specialized employees and contractors, including process technicians, laboratory analysts, engineers and microbiologists.
These new jobs have the potential to create a payroll impact of approximately $45 million for the region each year. Additionally, the Company estimates it could create approximately 5,000 construction jobs during the development of the site and that the investment will create an estimated economic impact of $3 billion statewide during the first 10 years of site operation.
“Johnson & Johnson is a recognized industry leader in pharmaceutical research, development and manufacturing, and we are proud to be part of the Wilson community,” said Dapo Ajayi, Vice President, Innovative Medicine Supply Chain, Johnson & Johnson. “This is a major investment and an exciting time as we start construction on this advanced manufacturing facility, using the latest technology and building a highly skilled workforce to deliver on our promise to patients.”